- Kadcyla
- Adcertis
- Others
Antibody Drug Conjugates Market size was valued at USD 4.84 billion in 2021 and is expected to reach USD 9.87 billion by 2028, at a CAGR of 12.6% during the forecast period 2022-2028. ADCs are a type of biopharmaceutical used to treat cancer that consists of an antibody that selectively targets a tumour antigen and a cytotoxic agent linked together by a chemical linker. ADCs are designed to allow the cytotoxic substance to be targeted specifically to kill cancer cells while having a minimal effect on healthy tissue. Antibody drug conjugates are made up of three parts: an antibody specific for the target associated antigen, an antigen that has limited expression on normal cells, a cytotoxic agent that kills target cancer cells, and a chemical linker that connects the cytotoxic agent to the antibody. Antibody drug conjugates have therapeutic potential but face technological and developmental obstacles. Antibody drug conjugates are thought to be the next generation of therapeutics. They combine the ability of monoclonal antibodies to target specific cells with the ability of cytotoxic medicines to kill those cells. Only with rising technological developments has this technology been able to succeed. Antibody drug conjugates are a new therapeutic class that is attracting the attention of both large and small pharmaceutical businesses. Key Development: In September 2017, Pfizer, Inc. received FDA approval for the Mylotarg (Gemtuzumab Ozogamicin), and antibody drug conjugate used in newly diagnosed and relapsed or refractory CD33-Positive acute myeloid leukemia.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The advancement of medical technology is projected to fuel the global market for antibody drug conjugates. The market's main drivers include an increase in cancer incidence, a growing elderly population, and an increase in obese people.
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
1. Executive Summary |
2. Global Antibody Drug Conjugate Market Introduction |
2.1. Global Antibody Drug Conjugate Market – Taxonomy |
2.2. Global Antibody Drug Conjugate Market –Definitions |
2.2.1. By Drugs |
2.2.2. By Mechanism Of Action |
2.2.3. By Application |
2.2.4. By Region |
3. Global Antibody Drug Conjugate Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Antibody Drug Conjugate Market Dynamic Factors - Impact Analysis |
3.6. Global Antibody Drug Conjugate Market – Competition Landscape |
4. Global Antibody Drug Conjugate Market Analysis, 2017-2021 and Forecast, 2022-2028 |
4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Antibody Drug Conjugate Market, By Drugs, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)Â |
5.1. Adcetris |
5.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Kadcyla |
5.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
6. Global Antibody Drug Conjugate Market, By Mechanism of Action, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)Â |
6.1. CD30 Antibodies |
6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. HER2 Antibodies |
6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7. Global Antibody Drug Conjugate Market Forecast, By Application, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)Â |
7.1. Breast Cancer |
7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Lymphoma |
7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
8. Global Antibody Drug Conjugate Market Forecast, By Region, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)Â |
8.1. North America |
8.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia-Pacific |
8.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Latin America |
8.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Middle East and Africa |
8.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
8.6. Global Antibody Drug Conjugate Market - Opportunity Analysis Index, By Drugs, By Mechanism Of Action, By Application and Region, 2022-2028 |
9. North America Antibody Drug Conjugate Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)Â |
9.1. Drugs Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.1.1. Adcetris |
9.1.2. Kadcyla |
9.2. Mechanism Of Action Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.2.1. CD30 Antibodies |
9.2.2. HER2 Antibodies |
9.3. Application Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.3.1. Breast Cancer |
9.3.2. Lymphoma |
9.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
9.4.1. USA |
9.4.2. Canada |
9.5. North America Antibody Drug Conjugate Market - Opportunity Analysis Index, By Drugs, By Mechanism of Action, By Application, and Country, 2022-2028 |
9.6. North America Antibody Drug Conjugate Market Dynamics – Trends |
10. Europe Antibody Drug Conjugate Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)Â |
10.1. Drugs Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Adcetris |
10.1.2. Kadcyla |
10.2. Mechanism Of Action Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.2.1. CD30 Antibodies |
10.2.2. HER2 Antibodies |
10.3. Application Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.3.1. Breast Cancer |
10.3.2. Lymphoma |
10.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
10.4.1. Germany |
10.4.2. UK |
10.4.3. France |
10.4.4. Spain |
10.4.5. Italy |
10.4.6. Russia |
10.4.7. Rest of Europe |
10.5. Europe Antibody Drug Conjugate Market - Opportunity Analysis Index, By Drugs, By Mechanism of Action, By Application, and Country, 2022-2028 |
10.6. Europe Antibody Drug Conjugate Market Dynamics – Trends |
11. Asia-Pacific Antibody Drug Conjugate Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)Â |
11.1. Drugs Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Adcetris |
11.1.2. Kadcyla |
11.2. Mechanism Of Action Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.2.1. CD30 Antibodies |
11.2.2. HER2 Antibodies |
11.3. Application Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.3.1. Breast Cancer |
11.3.2. Lymphoma |
11.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
11.4.1. China |
11.4.2. India |
11.4.3. Japan |
11.4.4. ASEAN |
11.4.5. Australia & New Zealand |
11.4.6. Rest of Asia-Pacific |
11.5. Asia-Pacific Antibody Drug Conjugate Market - Opportunity Analysis Index, By Drugs, By Mechanism of Action, By Application and Country, 2022-2028 |
11.6. Asia-Pacific Antibody Drug Conjugate Market Dynamics – Trends |
12. Latin America Antibody Drug Conjugate Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)Â |
12.1. Drugs Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Adcetris |
12.1.2. Kadcyla |
12.2. Mechanism Of Action Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.2.1. CD30 Antibodies |
12.2.2. HER2 Antibodies |
12.3. Application Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.3.1. Breast Cancer |
12.3.2. Lymphoma |
12.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
12.4.1. Brazil |
12.4.2. Mexico |
12.4.3. Argentina |
12.4.4. Rest of Latin America |
12.5. Latin America Antibody Drug Conjugate Market - Opportunity Analysis Index, By Drugs, By Mechanism of Action, By Application and Country, 2022-2028 |
12.6. Latin America Antibody Drug Conjugate Market Dynamics – Trends |
13. Middle East and Africa Antibody Drug Conjugate Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)Â |
13.1. Drugs Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.1.1. Adcetris |
13.1.2. Kadcyla |
13.2. Mechanism Of Action Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.2.1. CD30 Antibodies |
13.2.2. HER2 Antibodies |
13.3. Application Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.3.1. Breast Cancer |
13.3.2. Lymphoma |
13.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
13.4.1. Gulf Cooperation Council (GCC) Countries |
13.4.2. Israel |
13.4.3. South Africa |
13.4.4. Rest of MEA |
13.5. MEA Antibody Drug Conjugate Market - Opportunity Analysis Index, By Drugs, By Mechanism of Action, By Application and Country, 2022-2028 |
13.6. MEA Antibody Drug Conjugate Market Dynamics – Trends |
14. Competition Landscape |
14.1. Strategic Dashboard of Top Market Players |
14.2. Company Profiles (Introduction, Financial Analysis, Drugss, Key Developments, Strategies, and SWOT Analysis) |
14.2.1. F. Hoffman-La Roche Ltd. |
14.2.2. Novartis AG |
14.2.3. Takeda Pharmaceutical Company Limited |
14.2.4. Pfizer, Inc. |
14.2.5. Amar Chemistry |
14.2.6. Seattle Genetics Inc. |
14.2.7. Genentech Inc. |
14.2.8. Immunogen Inc. |
14.2.9. Immunomedics, Inc. |
14.2.10. Progenics Pharmaceuticals Inc. |
14.2.11. Bayer Healthcare Pharmaceuticals |
15. Research Methodology |
16. Key Assumptions and Acronyms |